Israeli researchers develop drug to help ALS patients
New drug candidate may prove effective in boosting the self-cleansing mechanism of the human brain, thereby improving the lives of millions of people.
New drug candidate may prove effective in boosting the self-cleansing mechanism of the human brain, thereby improving the lives of millions of people.
Israeli scientist finds effective ways of eliminating senescent cells that contribute to conditions such as Alzheimer’s and atherosclerosis.
SIRT6 is found to be necessary for the body’s DNA repair process, while low levels are seen in patients with neurodegenerative diseases.
Israeli company expects to begin commercializing its unique assay in 2017, applying for CE clearance in Europe.
Israel is one of 19 partners in breakthrough clinical trial showing nutritional cocktail may improve memory and reduce brain shrinkage.
Researchers find neuroprotective blood protein that is a biomarker for Alzheimer’s disease and also correlates with IQ.
Neuronix’s neuroAD is already commercially available in Europe, Asia and Israel for slowing disease progression in mild to moderate Alzheimer cases.
Using this discovery, University of Haifa scientists will attempt to develop drugs delaying the onset of cognitive symptoms of Alzheimer’s disease.
Israeli biotech NeuroQuest set to start US clinical trial of its simple test to diagnose the dreaded brain disorder in older individuals at risk.
Raises $28 million to expand commercial and clinical adoption of Brain Network Activation system in US and Europe.
Israeli researchers propose that the degenerative brain disorder can result from separate causes that must be classified and treated separately.
IBM Research Lab in Haifa is working on technology to develop mobile apps for the diagnosis of two very common brain disorders.
Ahead of BrainTech2015 in Tel Aviv, Israel Brain Technologies director tells ISRAEL21c about some amazing advances.
Critical finding reveals atomic structure of a protein link between Type 2 diabetes and neurodegenerative diseases such as Parkinson’s.
Hebrew University’s tech-transfer company, Yissum, partners with the likes of J&J, P&G, Merck, Roche, Novartis, Microsoft, Intel, Coca-Cola and Monsanto.